Cost–effectiveness models of pneumococcal conjugate vaccines: Variability and impact of modeling assumptions

Expert Review of Vaccines

Volumn 11, Issue 10, 2012, Pages 1235-1247

  Farkouh, Raymond a ^a   Klok, Rogier m ^a   Postma, Maarten j ^b   Roberts, Craig s ^a   Strutton, David r ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

acute otitis media; cost effectiveness analysis; cross protection; herd effects; invasive pneumococcal disease; nontypable Haemophilus influenzae; PCV10; PCV13; PCV7; PHiD CV; pneumococcal conjugate vaccine; pneumonia

Indexed keywords

10 VALENT PNEUMOCOCCAL VACCINE; 10-VALENT PNEUMOCOCCAL VACCINE; 13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; PNEUMOCOCCUS VACCINE;

COST BENEFIT ANALYSIS; CROSS PROTECTION; ECONOMICS; HUMAN; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; REVIEW; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; CROSS PROTECTION; HUMANS; MODELS, STATISTICAL; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 84873589183     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.99     Document Type: Article

References (63)

1. Pilishvili T, Lexau C, Farley MM et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network.Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201 (1), 32 – 41 (2010).
2. Miller E, Andrews NJ, Waight PA, Slack MP, George RC.Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29 (49), 9127 – 9131 (2011).
3. Black S, Shinefield H, Fireman B et al.Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19 (3), 187 – 195 (2000).
4. Black SB, Shinefield HR, Ling S et al.Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21 (9), 810 – 815 (2002).
5. Prymula R, Peeters P, Chrobok V et al.Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367 (9512), 740 – 748 (2006).
6. Moore M, Link-Gelles R, Farley M et al.Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010–11. Presented at: The 8th International Symposium on Pneumococci and Pneumococcal Diseases. Foz do Iguaçu, Brazil, 11–15 March 2012.
7. Morano R, Pérez F, Brosa M, Pérez Escolano I.[Cost–effectiveness analysis of pneumococcal vaccination in Spain]. Gac. Sanit. 25 (4), 267 – 273 (2011).
8. De Wals P, Black S, Borrow R, Pearce D.Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin. Ther. 31 (10), 2152 – 2169 (2009).
9. Chuck AW, Jacobs P, Tyrrell G, Kellner JD.Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine 28 (33), 5485 – 5490 (2010).
10. Newall AT, Creighton P, Philp DJ, Wood JG, MacIntyre CR.The potential cost–effectiveness of infant pneumococcal vaccines in Australia. Vaccine 29 (45), 8077 – 8085 (2011).
11. Rubin JL, McGarry LJ, Strutton DR et al.Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 28 (48), 7634 – 7643 (2010).
12. Strutton DR, Farkouh RA, Earnshaw SR et al.
13. Talbird SE, Taylor TN, Knoll S, Frostad CR, García Martí S.Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine 28 (Suppl. 6), G23 – G29 (2010).
14. Muciño-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D.[Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines]. Value Health 14 (5 Suppl. 1), S65 – S70 (2011).
15. Sartori AM, de Soárez PC, Novaes HM.Cost–effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. J. Epidemiol. Community Health 66 (3), 210 – 217 (2012).
16. Urueña A, Pippo T, Betelu MS et al.Cost–effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine 29 (31), 4963 – 4972 (2011).
17. Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AK.Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine 29 (47), 8564 – 8574 (2011).
18. Knerer G, Ismaila A, Pearce D.Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J. Med. Econ. 15 (1), 61 – 76 (2012).
19. Rozenbaum MH, Sanders EA, van Hoek AJ et al.Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 340, c2509 (2010).
20. Kim SY, Lee G, Goldie SJ.Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infect. Dis. 10, 260 (2010).
21. Tyo KR, Rosen MM, Zeng W et al.Cost–effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 29 (38), 6686 – 6694 (2011).
22. Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, Puig-Barberá J, Lluch-Rodrigo JA, Pastor-Villalba E.Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine 29 (52), 9640 – 9648 (2011).
23. Eskola J, Kilpi T, Palmu A et al.; Finnish Otitis Media Study Group.Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344 (6), 403 – 409 (2001).
24. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P.Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22 (1), 10 – 16 (2003).
25. Castañeda E, Agudelo CI, Regueira M et al.; SIREVA II Group.Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr. Infect. Dis. J. 28 (9), e265 – e270 (2009).
26. Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA.Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J. Infect. Dis. 201 (10), 1570 – 1579 (2010).
27. Hausdorff WP, Yothers G, Dagan R et al.Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr. Infect. Dis. J. 21 (11), 1008 – 1016 (2002).
28. Whitney CG, Pilishvili T, Farley MM et al.Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 (9546), 1495 – 1502 (2006).
29. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR.Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 (9568), 1179 – 1186 (2007).
30. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr. Infect. Dis. J. 23 (12), 1142 – 1152 (2004).
31. Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review. Pharmacoeconomics 29 (3), 199 – 211 (2011).
32. Prymula R, Hanovcova I, Splino M et al.Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 29 (10), 1959 – 1967 (2011).
33. Lieu TA, Ray GT, Black SB et al.Projected cost–effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283 (11), 1460 – 1468 (2000).
34. Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ.Enhanced decision support for policy makers using a web interface to health-economic models – illustrated with a cost–effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in The Netherlands. Vaccine 25 (18), 3669 – 3678 (2007).
35. Bos JM, Rümke H, Welte R, Postma MJ.Epidemiologic impact and cost–effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in The Netherlands. Clin. Ther. 25 (10), 2614 – 2630 (2003).
36. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB.Cost–effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J. 25 (6), 494 – 501 (2006).
37. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.Cost–effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur. J. Health Econ. 9 (1), 7 – 15 (2008).
38. McIntosh ED, Conway P, Willingham J, Hollingsworth R, Lloyd A.Pneumococcal pneumonia in the UK – how herd immunity affects the cost–effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 23 (14), 1739 – 1745 (2005).
39. Whitney CG, Farley MM, Hadler J et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network.Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med. 348 (18), 1737 – 1746 (2003).
40. Ho PL, Chiu SS, Chan MY, Ang I, Chow KH, Lau YL.Changes in nasopharyngeal carriage and serotype distribution of antibiotic-resistant Streptococcus pneumoniae before and after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong. Diagn. Microbiol. Infect. Dis. 71 (4), 327 – 334 (2011).
41. C., García-Vera, M., Ruiz Andrés, MÁ, T., Arana Navarro, et al., Nasopharyngeal carriage of pneumococcal serotypes in healthy pre-school aged children after 7-valent pneumococcal vaccine, Med. Clin. (Barc.)., (2011), 137, 1, 1-7
42. Flasche S, Van Hoek AJ, Sheasby E et al.Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 8 (4), e1001017 (2011).
43. Kim KH, Hong JY, Lee H et al.Nasopharyngeal pneumococcal carriage of children attending day care centers in Korea: comparison between children immunized with 7-valent pneumococcal conjugate vaccine and non-immunized. J. Korean Med. Sci. 26 (2), 184 – 190 (2011).
44. Huang SS, Hinrichsen VL, Stevenson AE et al.Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 124 (1), e1 – 11 (2009).
45. R., Prymula, P., Kriz, E., Kaliskova, T., Pascal, J., Poolman, L., Schuerman, Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age, Vaccine, (2009), 28, 1, 71-78
46. Tregnaghi MW, Sáez-Llorens X, López P et al.Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-d conjugate vaccine (PHID-CV) against community-acquired pneumonia in Latin America. Presented at: The 29th Annual Meeting of the European Society for Paediatric Infectious Diseases. The Hague, The Netherlands, 7–11 June 2011.
47. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E.Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr. Infect. Dis. J. 31 (3), 297 – 301 (2012).
48. Dagan R, Givon-Lavi N, Porat N, Greenberg D.The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine 30 (34), 5132 – 5140 (2012).
49. Dagan R, Patterson S, Juergens C et al.Efficacy of 13-valent and 7-valent pneumococcal conjugate vaccine (PCV13; PCV7) in preventing nasopharyngeal colonization with PCV7-serotypes: a randomized double-blind trial. Presented at: The 8th International Symposium on Pneumococci & Pneumococcal Diseases. Iguaçu Falls, Brazil, 11–15 March 2012
50. Flasche S, Slack M, Miller E.Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Euro Surveill. 16 (20), 19868 (2011).
51. Hicks LA, Harrison LH, Flannery B et al.Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J. Infect. Dis. 196 (9), 1346 – 1354 (2007).
52. Vesikari T, Wysocki J, Chevallier B et al.Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr. Infect. Dis. J. 28 (Suppl. 4), S66 – S76 (2009).
53. Hanage WP, Bishop CJ, Lee GM et al.Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination. Vaccine 29 (48), 8877 – 8881 (2011).
54. van Gils EJ, Veenhoven RH, Hak E et al.Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 304 (10), 1099 – 1106 (2010).
55. Pelton SI, Huot H, Finkelstein JA et al.Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26 (6), 468 – 472 (2007).
56. Kieninger DM, Kueper K, Steul K et al.; 006 study group.Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 28 (25), 4192 – 4203 (2010).
57. De Wals P, Lefebvre B, Deceuninck G, Bourgault AM.Invasive pneumococcal disease in two birth cohorts vaccinated, respectively, with 2+1 PCV-7 or PHID-CV-10 doses. Presented at: The 29th Annual Meeting of the European Society for Paediatric Infectious Diseases. The Hague, The Netherlands, 7–11 June 2011.
58. Johnson HL, Deloria-Knoll M, Levine OS et al.Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 7 (10), e1000348 (2010).
59. United Nations Environment Programme. Limitations of cost–benefit analysis. www.unep.org/dec/onlinemanual/Enforcement/NationalLawsRegulations/Resource/tabid/777/Default.aspx (Accessed 30 November 2011)
60. Synflorix product description. www.medicines.org.uk/emc/document.aspx?documentid=22743&docType=SPC (Accessed 10 November 2011)
61. Prevenar 13 product description. http://labeling.pfizer.com/showlabeling.aspx?id=501 (Accessed 10 November 2011)
62. Synflorix Public Assessment report. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000973/WC500054349.pdf (Accessed 17 January 2012)
63. Moore M, Link-Gelles R, Farley M et al. Early impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old, U.S, 2010. ICAAC Annual Meeting 2011. Presentation #G1-538. www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=6ffe8b06-3097-45ff-807e-3c59e8b9dee4&cKey=7566da3a-4114-4bc9-afdc-0f99d9548db3&mKey=0C918954-D607-46A7-8073-44F4B537A439v (Accessed October 2011)